BAY-3827 is a selective and potent inhibitor of AMPK (AMP-activated protein kinase) and RSK1 (ribosomal 6 kinase 1) that exhibit strong anti-proliferative activity in androgen-dependent prostate cancer cell lines. BAY-3827 strongly down-regulates lipase E (LIPE), cAMP-dependent protein kinase type II-beta regulatory subunit (PRKAR2B), serine-threonine kinase AKT3 and carnitine palmitoyl-transferase 1 (CPT1) family expression levels and impairs lipid flux.
Selective and potent inhibitor of AMPK and RSK1 that exhibit strong anti-proliferative activity in androgen-dependent prostate cancer cell lines
Rab8a as a mitochondrial receptor for lipid droplets in skeletal muscle
Developmental Cell, 58(4), 289-305 (2023)
Anti-Na+/K+-ATPase DR antibody attenuates UUO-induced renal fibrosis through inhibition of Na+/K+-ATPase ?1-dependent HMGB1 release
Zheng J, Lan P, Li M, Kang MC, Xun M, Ma X, Yan M, Sun D, Shen Y, Fu X, Ding X, Yan X, Xue WJ
International Immunopharmacology, 116, 109826-109826 (2023)
The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models
Cellular oncology, 44(3), 581-594 (2021)
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.